A Study of Omega-3 as a Treatment for Major Depression
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00238758
Verified September 2006 by The University of New South Wales. Recruitment status was: Recruiting
The purpose of this study is to determine whether omega-3 polyunsaturated fatty acids are effective as a monotherapy for depression.
Condition or disease
Drug: Omega-3 Polyunsaturated Fatty Acids
The study will be a 6 week, parallel-group, double-blind randomized controlled trial of the efficacy of Omega-3 as a monotherapy for depression. People aged 21-65 who have major depression but are not currently on an antidepressant or planning to take an antidepressant in the next 14 weeks will be recruited. Participants will be randomly allocated to receive Omega-3 (fish oil) or placebo (paraffin oil) for 6 weeks. Participants will be followed up weekly and will be asked to rate their mood daily for the 6 week study period. Blood samples will be taken pre and post treatment to measure change in omega-3 levels. At the end of 6 weeks all participants will receive a further 8 weeks supply of omega-3.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study:
21 Years to 65 Years (Adult)
Sexes Eligible for Study:
Accepts Healthy Volunteers:
Must meet DSM IV criteria for non-psychotic major depression lasting at least 6 weeks or dysthymia.
Must be under the care of a mental health practitioner.
Must be able to give informed consent.
Must be able to attend the Black Dog Institute.
Unsuccessful treatment with more than 2 antidepressant medications (at therapeutically adequate doses and duration.
History of psychosis or mania/hypomania or personality disorder.
Non-English speaking or otherwise unable to provide historical information.
Having taken Omega-3 dietary supplements in the last 3 months.
Taking antidepressant medication for depression.
History of allergy to n-3 PUFA supplements, finfish or shellfish.
Pregnancy, breast feeding or planning to become pregnant during course of study.
Current drug or alcohol abuse or dependence or history of abuse or dependence over the last 12 months.
Unstable thyroid function
Hepatic or renal impairment or other medical conditions that may interfere with the absorption and metabolism of omega-3 polyunsaturated fatty acids.
Coagulopathy or anticoagulant treatment.
Patients who, in the investigator's judgment pose a current serious suicidal or other safety risk, or patients who are not likely to be able to comply with the study protocol.